期刊
JOURNAL OF PHARMACY AND PHARMACOLOGY
卷 74, 期 12, 页码 1677-1688出版社
OXFORD UNIV PRESS
DOI: 10.1093/jpp/rgac063
关键词
doxorubicin; cancer; oxidative stress; cardiotoxicity; ROS; iron
Doxorubicin is widely used as a chemotherapeutic agent, but its cardiotoxicity limits its application. The understanding of Doxorubicin metabolism and mechanisms of action is still incomplete, and the mechanisms of Doxorubicin-induced cardiotoxicity are multifactorial and involve oxidative stress. Novel delivery systems and antioxidant therapies are important for reducing cardiotoxicity.
Objectives Doxorubicin (Dox) belongs to the anthracycline drug classification and is a widely administered chemotherapeutic. However, Dox use in therapy is limited by its cardiotoxicity, representing a significant drawback of Dox treatment applicability. A large amount of current research is on reducing Dox-induced cardiotoxicity by developing targeted delivery systems and investigating cardiotoxicity mechanisms. Recently, discrepancies have challenged the traditional understanding of Dox metabolism, mechanisms of action and cardiotoxicity drivers. This review summarises the current knowledge around Dox's metabolism, mechanisms of anticancer activity, and delivery systems and offers a unique perspective on the relationships between several proposed mechanisms of Dox-induced cardiotoxicity. Key findings While there is a strong understanding of Dox's pharmacokinetic properties, it is unclear which enzymes contribute to Dox metabolism and how Dox induces its cytotoxic effect in neoplastic and non-neoplastic cells. Evidence suggests that there are several potentially synergistic mechanisms involved in Dox-induced cardiotoxicity. It has become clear that Dox operates in a multifactorial fashion dependent on cellular context. Accumulation of oxidative stress appears to be a common factor in cardiotoxicity mechanisms, highlighting the importance of novel delivery systems and antioxidant therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据